Perrigo Quarterly Income Statement
NYSE: PRGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Perrigo revenue and earnings
In the quarter ended Jun 27, 2026, Perrigo generated $1.02 billion in revenue, down 3.2% from the same quarter a year earlier. Net income was $74.5 million, for a net margin of 7.3% versus a median of -0.8% in the prior 5 quarters. Gross margin was 30.7% (down from 34.4%) and operating margin 2.3%.
Diluted earnings per share came in at $0.53.
Summary generated from market data by MetaCap's automated system. Methodology
Perrigo income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-27 | Q1 20262026-03-28 | Q4 20252025-12-31 | Q3 20252025-09-27 | Q2 20252025-06-28 | Q1 20252025-03-29 | Q4 20242024-12-31 | Q3 20242024-09-28 | Q2 20242024-06-29 | Q1 20242024-03-30 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.02B | 969.20M | 1.11B | 1.04B | 1.06B | 1.04B | 1.14B | 1.09B | 1.07B | 1.08B | 1.16B | 1.12B |
| Revenue growth (YoY) | -3.17% | -7.16% | -2.52% | -4.06% | -0.86% | -3.53% | -1.61% | -3.23% | -10.69% | -8.43% | +0.14% | +2.15% |
| Cost of Revenue | 708.90M | 643.70M | 747.40M | 666.20M | 693.40M | 651.60M | 752.40M | 683.10M | 670.80M | 724.40M | 729.60M | 712.60M |
| Gross Profit | 313.90M | 325.50M | 362.20M | 377.10M | 362.90M | 392.30M | 385.90M | 404.40M | 394.70M | 357.70M | 427.30M | 411.20M |
| Operating Expenses | 290.50M | 697.80M | 1.65B | 304.50M | 317.50M | 345.40M | 271.70M | 324.00M | 421.20M | 412.90M | 442.90M | 349.10M |
| Research & Development | 23.70M | 24.60M | 21.80M | 24.90M | 22.00M | 26.70M | 27.80M | 26.00M | 29.40M | 29.00M | 29.60M | 29.60M |
| Selling, General & Admin | 229.50M | 244.70M | 233.10M | 221.50M | 249.50M | 258.40M | 211.50M | 246.30M | 276.20M | 280.70M | 281.30M | 276.20M |
| Operating Income | 23.50M | -372.30M | -1.29B | 72.60M | 45.40M | 46.90M | 114.20M | 80.40M | -26.50M | -55.20M | -15.60M | 62.10M |
| Other Income (Expense) | 120.50M | 6.00M | -1.30M | -9.60M | -2.60M | 400.00K | 400.00K | 4.10M | -3.40M | -400.00K | 800.00K | 600.00K |
| Pretax Income | 105.40M | -408.50M | -1.33B | 22.40M | 3.20M | 8.30M | 70.00M | 21.80M | -74.00M | -98.60M | -54.30M | 19.20M |
| Income Tax | 16.90M | -18.70M | 82.90M | 9.70M | 3.70M | 8.20M | 111.50M | 39.40M | 31.70M | -102.70M | -26.60M | 3.80M |
| Net Income | 74.50M | -398.60M | -1.42B | 7.50M | -8.40M | -6.40M | -44.50M | -21.00M | -108.40M | 2.00M | -32.30M | 14.20M |
| Net Income growth (YoY) | — | — | — | — | — | -420.00% | — | -247.89% | -1390.48% | — | — | — |
| EPS (Basic) | 0.54 | -2.87 | -10.23 | 0.05 | -0.06 | -0.05 | -0.32 | -0.15 | -0.79 | 0.01 | -0.23 | 0.10 |
| EPS (Diluted) | 0.53 | -2.87 | -10.23 | 0.05 | -0.06 | -0.05 | -0.32 | -0.15 | -0.79 | 0.01 | -0.23 | 0.10 |
| Shares Outstanding (Basic) | 139.10M | 138.70M | — | 138.50M | 138.20M | 137.70M | — | 137.50M | 137.10M | 136.60M | — | 135.50M |
| Shares Outstanding (Diluted) | 139.60M | 138.70M | — | 138.90M | 138.20M | 137.70M | — | 137.50M | 137.10M | 137.60M | — | 136.90M |
| EBITDA | 119.30M | -289.00M | -1.20B | 158.00M | 131.70M | 126.80M | 194.50M | 162.70M | 55.40M | 26.20M | 70.30M | 153.10M |
| Gross Margin | 30.69% | 33.58% | 32.64% | 36.14% | 34.36% | 37.58% | 33.90% | 37.19% | 37.04% | 33.06% | 36.93% | 36.59% |
| Operating Margin | 2.30% | -38.41% | -116.00% | 6.96% | 4.30% | 4.49% | 10.03% | 7.39% | -2.49% | -5.10% | -135.00% | 5.53% |
| Net Margin | 7.28% | -41.13% | -127.80% | 72.00% | -80.00% | -61.00% | -3.91% | -1.93% | -10.17% | 18.00% | -2.79% | 126.00% |
This table shows 12 quarterly periods of Perrigo's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PRGO's reporting calendar. What is a income statement?